Cockayne syndrome

ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)

Retrieved on: 
Thursday, January 12, 2023
Health, Genetics, General Health, Research, Science, Biotechnology, Neurodegeneration, XPA, ChromaDex, SAB, University of Copenhagen Center for Planetary Research, Teaching hospital, University, Ageing, Publication, NR, Molecular biology, Xeroderma pigmentosum, DNA, University Hospital (Newark, New Jersey), Degenerative disease, City, NAD, Stanford University, National Institutes of Health, Neurology, DNA repair, Infection, Oxidative stress, Laboratory, National Institute on Aging, Research, Cockayne syndrome, NIH, Cell, United States Air Force Scientific Advisory Board, Medical device, Diabetes, Ataxia–telangiectasia, Biochemistry

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc.
  • Dr. Bohr is one of the world’s most published researchers on aging and neurodegenerative disease with over 590 journal publications.
  • His research has been conducted in models of Alzheimer’s disease, age-related hearing loss and other conditions resulting from age-related decline.
  • “Dr.

Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC® (secnidazole) in Adolescents for both the Treatment of Bacterial Vaginosis in Females and Trichomoniasis

Retrieved on: 
Thursday, February 17, 2022
Energy drink, Woman, Propylene glycol, Prevalence, Abdominal pain, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lupinus, Liver failure, Yogurt, Risk, Private Securities Litigation Reform Act, Gaps, Cockayne syndrome, Trichomoniasis, Health, New Drug Application, Vaginitis, Sex, Patient, Bacterial vaginosis, Shanda, Candidiasis, Diarrhea, Female, National Health and Nutrition Examination Survey, Vertically transmitted infection, BV, Patent, Ethanol, Lupin Limited, Sexually transmitted infection, Human, Metronidazole, Headache, Infection, CDC, Incidence, Vomiting, Vaginal yeast infection, National Health, Secnidazole, Reproductive health, Food, Environment, STI, FDA, Prescription, Nausea, Partner (business rank), Dysgeusia, Pharmaceutical industry, Birth control, Legume, Adolescence

"The FDA's approval expands the indication for SOLOSEC to treat adolescents and builds upon our commitment to support women's health.

Key Points: 
  • "The FDA's approval expands the indication for SOLOSEC to treat adolescents and builds upon our commitment to support women's health.
  • Vulvovaginal candidiasis may develop with SOLOSEC and require treatment with an antifungal agent.
  • To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-844-SOLOSEC (1-844-765-6732) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
  • SOLOSEC is a registered trademark of Lupin Inc. and LUPIN is a registered trademark of Lupin Pharmaceuticals, Inc.